Alnylam Pharmaceuticals Inc (ALNY)vsGenerate Biomedicines, Inc. Common Stock (GENB)
ALNY
Alnylam Pharmaceuticals Inc
$303.00
+0.63%
HEALTHCARE · Cap: $39.51B
GENB
Generate Biomedicines, Inc. Common Stock
$15.30
-0.78%
HEALTHCARE · Cap: $1.97B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 13342% more annual revenue ($4.29B vs $31.89M). ALNY leads profitability with a 12.6% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
GENB
Avoid16
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.7%
Fair Value
$2420.83
Current Price
$303.00
$2117.83 discount
Intrinsic value data unavailable for GENB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 90 in profit
Revenue surging 96.4% year-over-year
Growing faster than its price suggests
Strong operational efficiency at 23.0%
No standout strengths identified
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 50.8x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth, PEG Ratio. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : GENB
GENB has a balanced fundamental profile.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 74.6x leaves little room for execution misses.
Bear Case : GENB
The primary concerns for GENB are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a growth stock while GENB is a value play — different risk/reward profiles.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (65/100 vs 16/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Generate Biomedicines, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Generate Biomedicines, Inc. is an innovative biotechnology company focused on harnessing the power of genetic engineering to develop protein therapeutics for a range of diseases. By leveraging advanced artificial intelligence and machine learning technologies, Generate Biomedicines aims to streamline the drug discovery process, significantly reducing time and costs associated with traditional methods. The company's proprietary platform enables the rapid design and optimization of therapeutic proteins, positioning it at the forefront of the biopharmaceutical industry. With a strong commitment to improving patient outcomes, Generate Biomedicines continues to expand its pipeline and collaborate with leading partners to bring transformative treatments to market.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?